Rowena J. Dolor

Rowena J. Dolor

Auto-generated profile, based on publicly available information

Rowena J. Dolor

Division of General Internal Medicine, Department of Medicine, Duke University School of Medicine , Durham, NC

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2015 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PDPamela S. Douglas
Pamela S. Douglas
UHUdo Hoffmann
Udo Hoffmann
MPManesh R. Patel
Manesh R. Patel
DMDaniel B. Mark
Daniel B. Mark
HAHussein R. Al-Khalidi
Hussein R. Al-Khalidi
KLKerry L. Lee
Kerry L. Lee
Many patients have symptoms suggestive of coronary artery disease (CAD) and are often evaluated with the use of diagnostic testing, although there are limited data from randomized trials to guide care. We randomly assigned 10,003 symptomatic patients to a strategy of initial anatomical testing with the use of coronary computed tomographic angiography (CTA) or to functional testing (exercise electrocardiography, nuclear stress testing, or stress echocardiography). The composite primary end point was death, myocardial infarction, hospitalization for unstable angina, or major procedural complication. Secondary end points included invasive cardiac catheterization that did not show obstructive CAD and radiation exposure. The mean age of the patients was 60.8±8.3 years, 52.7% were women, and 87.7% had chest pain or dyspnea on exertion. The mean pretest likelihood of obstructive CAD was 53.3±21.4%. Over a median follow-up period of 25 months, a primary end-point event occurred in 164 of 4996 patients in the CTA group (3.3%) and in 151 of 5007 (3.0%) in the functional-testing group (adjusted hazard ratio, 1.04; 95% confidence interval, 0.83 to 1.29; P=0.75). CTA was associated with fewer catheterizations showing no obstructive CAD than was functional testing (3.4% vs. 4.3%, P=0.02), although more patients in the CTA group underwent catheterization within 90 days after randomization (12.2% vs. 8.1%). The median cumulative radiation exposure per patient was lower in the CTA group than in the functional-testing group (10.0 mSv vs. 11.3 mSv), but 32.6% of the patients in the functional-testing group had no exposure, so the overall exposure was higher in the CTA group (mean, 12.0 mSv vs. 10.1 mSv; P<0.001). In symptomatic patients with suspected CAD who required noninvasive testing, a strategy of initial CTA, as compared with functional testing, did not improve clinical outcomes over a median follow-up of 2 years. (Funded by the National Heart, Lung, and Blood Institute; PROMISE ClinicalTrials.gov number, NCT01174550.)

22 March 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
LMLori Mosca
Lori Mosca
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
KBKathy Berra
Kathy Berra
JBJudy L. Bezanson
Judy L. Bezanson
RDRowena J. Dolor
Rowena J. Dolor
NWNanette K. Wenger
Nanette K. Wenger

1 March 2011 in JACC
Verified
Journal Article
Closed access
LMLori Mosca
Lori Mosca
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
KBKathy Berra
Kathy Berra
JBJudy L. Bezanson
Judy L. Bezanson
RDRowena J. Dolor
Rowena J. Dolor
NWNanette K. Wenger
Nanette K. Wenger

20 March 2007 in Circulation
Verified
Journal Article
Closed access
LMLori Mosca
Lori Mosca
CBCarole L. Banka
Carole L. Banka
Emelia J. BenjaminEmelia J. Benjamin
Emelia J. Benjamin
KBKathy Berra
Kathy Berra
CBCheryl Bushnell
Cheryl Bushnell
NWNanette K. Wenger
Nanette K. Wenger

5 February 2013 in Annals of Internal Medicine
Verified
Journal Article
Open access
PDF file
GJGeorge L. Jackson
George L. Jackson
BPBenjamin J. Powers
Benjamin J. Powers
RCRanee Chatterjee
Ranee Chatterjee
JBJanet Prvu Bettger
Janet Prvu Bettger
AKAlex R. Kemper
Alex R. Kemper
JWJohn W. Williams
John W. Williams
Background: The patient-centered medical home (PCMH) describes mechanisms for organizing primary care to provide high-quality care across the full range of individuals' health care needs. It is being widely implemented by provider organizations and third-party payers. Purpose: To describe approaches for PCMH implementation and summarize evidence for effects on patient and staff experiences, process of care, and clinical and economic outcomes. Data Sources: PubMed (through 6 December 2011), Cumulative Index to Nursing & Allied Health Literature, and the Cochrane Database of Systematic Reviews (through 29 June 2012). Study Selection: English-language trials and longitudinal observational studies that met criteria for the PCMH, as defined by the Agency for Healthcare Research and Quality, and included populations with multiple conditions. Data Extraction: Information on study design, populations, interventions, comparators, financial models, implementation methods, outcomes, and risk of bias were abstracted by 1 investigator and verified by another. Data Synthesis: In 19 comparative studies, PCMH interventions had a small positive effect on patient experiences and small to moderate positive effects on the delivery of preventive care services (moderate strength of evidence). Staff experiences were also improved by a small to moderate degree (low strength of evidence). Evidence suggested a reduction in emergency department visits (risk ratio [RR], 0.81 [95% CI, 0.67 to 0.98]) but not in hospital admissions (RR, 0.96 [CI, 0.84 to 1.10]) in older adults (low strength of evidence). There was no evidence for overall cost savings. Limitation: Systematic review is challenging because of a lack of consistent definitions and nomenclature for PCMH. Conclusion: The PCMH holds promise for improving the experiences of patients and staff and potentially for improving care processes, but current evidence is insufficient to determine effects on clinical and most economic outcomes.

1 March 2010 in Circulation: Cardiovascular Quality and Outcomes
Verified
Journal Article
Closed access
CMChiara Melloni
Chiara Melloni
JBJeffrey S. Berger
Jeffrey S. Berger
TWTracy Y. Wang
Tracy Y. Wang
FGFunda Gunes
Funda Gunes
ASAmanda Stebbins
Amanda Stebbins
LNL. Kristin Newby
L. Kristin Newby
Background— The 2007 American Heart Association guidelines for cardiovascular disease prevention in women drew heavily on results from randomized clinical trials; however, representation of women in trials of cardiovascular disease prevention has not been systematically assessed. Methods and Results— We abstracted 156 randomized clinical trials cited by the 2007 women’s prevention guidelines to determine female representation over time and by clinical indication, prevention type, location of trial conduct, and funding source. Both women and men were represented in 135 of 156 (86.5%) trials; 20 trials enrolled only men; 1 enrolled only women. Among all trials, the proportion of women increased significantly over time, from 9% in 1970 to 41% in 2006. Considering only trials that enrolled both women and men, female enrollment was 18% in 1970 and increased to 34% in 2006. Female representation was higher in international versus United States–only trials (32.7% versus 26.7%) and primary versus secondary prevention trials (42.6% versus 26.6%). Female enrollment was comparable in government/foundation-funded versus industry-funded trials (31.9% versus 31.5%). Representation of women was highest among trials in hypertension (44%), diabetes (40%), and stroke (38%) and lowest for heart failure (29%), coronary artery disease (25%), and hyperlipidemia (28%). By contrast, women accounted for 53% of all individuals with hypertension, 50% with diabetes, 51% with heart failure, 49% with hyperlipidemia, and 46% with coronary artery disease. Sex-specific results were discussed in only 31% of primary trial publications. Conclusions— Enrollment of women in randomized clinical trials has increased over time but remains low relative to their overall representation in disease populations. Efforts are needed to reach a level of representation that is adequate to ensure evidence-based sex-specific recommendations.